Long-standing Dermatitis Treated With Dupilumab With Subsequent Progression to Cutaneous T-cell Lymphoma
| Autor: | Paul Wirth, Gregory J Fulchiero, Galen T Foulke, L. Claire Hollins |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Exacerbation Biopsy Eczema Dermatitis Disease Antibodies Monoclonal Humanized 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases medicine Humans Psoriasis Psoriasiform Dermatitis Interleukin-13 medicine.diagnostic_test business.industry Cutaneous T-cell lymphoma Off-Label Use Middle Aged medicine.disease Dermatology Dupilumab Lymphoma T-Cell Cutaneous Blockade Lymphoma 030220 oncology & carcinogenesis Disease Progression Female business |
| Zdroj: | Cutis. 106 |
| DOI: | 10.12788/cutis.0074 |
| Popis: | This case series discusses 3 patients with long-standing eczematous or psoriasiform dermatitis, demonstrated by multiple biopsies. Following off-label treatment with dupilumab, all 3 patients had clinical expansion of disease, with histopathologic features consistent with cutaneous T-cell lymphoma (CTCL) on subsequent biopsy. We postulate that this expansion likely was secondary to an exacerbation of extant CTCL following exposure to dupilumab. A proposed mechanism of promotion of CTCL is based on the functional increase in IL-13 available for binding at the upregulated IL-13 receptor (IL-13R) α2 site on cells, following blockade of the α1 receptor with dupilumab. This progression merits further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|